Peptides Codex
ENFR
← Home
Incretin mimetic (GLP-1 receptor agonist)

Lixisenatide

Lixisenatide is a synthetic GLP-1 receptor agonist built on the exendin-4 scaffold rather than on human GLP-1. Marketed as Lyxumia and Adlyxin, it is an approved prescription medicine in the EU and United States and a useful case study in how venom-derived peptides are adapted into once-daily therapeutics.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
44 aa
Class
Incretin mimetic (GLP-1 receptor agonist)
Function
Exendin-4-based GLP-1 receptor agonist
Context
Approved prescription medicine (EU and United States); prescription only

An exendin-4-derived GLP-1 agonist — the venom lineage engineered into a once-daily drug.

Also known as: Lyxumia · Adlyxin · AVE0010

Part of the Metabolic & GLP-1 peptides cluster

Overview

Lixisenatide is a synthetic GLP-1 receptor agonist built on the exendin-4 scaffold rather than on human GLP-1. Marketed as Lyxumia and Adlyxin, it is an approved prescription medicine in the EU and United States and a useful case study in how venom-derived peptides are adapted into once-daily therapeutics.

Source & context

Biological / chemical source: Synthetic peptide (des-Pro exendin-4 analog with a poly-lysine tail)

Primary research or clinical context: Approved prescription medicine (EU and United States); prescription only

Exendin-4 heritage

Like exenatide, lixisenatide descends from exendin-4, the DPP-4-resistant GLP-1 mimic originally found in Gila monster venom. It removes a proline and adds a chain of six lysine residues at the C-terminus, changes that tune its receptor engagement and pharmacokinetics — a clear example of scaffold-based peptide drug design.

Regulatory status

Lixisenatide is a regulated prescription product, not a research chemical. This page describes its chemistry and approval history for educational purposes only. Any use of prescription medicines belongs with a licensed clinician, and this content is not dosing or treatment advice.

FAQ about Lixisenatide

What is Lixisenatide?+

Lixisenatide is a synthetic GLP-1 receptor agonist built on the exendin-4 scaffold rather than on human GLP-1. Marketed as Lyxumia and Adlyxin, it is an approved prescription medicine in the EU and United States and a useful case study in how venom-derived peptides are adapted into once-daily therapeutics.

Is Lixisenatide an approved medicine?+

Lixisenatide: Approved prescription medicine (EU and United States); prescription only. Always follow licensed medical guidance for approved products.

What is the typical length of Lixisenatide?+

Lixisenatide is commonly described as approximately 44 amino acids (Incretin mimetic (GLP-1 receptor agonist)).

Related peptides

ACE-031
ActRIIB decoy-receptor fusion protein
ACE-031 is an engineered decoy receptor made by fusing the extracellular domain of the activin receptor type IIB (ActRIIB) to an IgG1 Fc fragment. It binds myostatin and related ligands to block their signaling. It is investigational, its clinical development was halted, and it is not approved; this page is educational only.
Larazotide
Tight-junction regulator peptide
Larazotide (larazotide acetate, AT-1001) is a synthetic eight-amino-acid peptide studied as a regulator of intestinal tight junctions, the seals between gut lining cells. It was investigated in celiac disease research. Its Phase 3 program was discontinued and it is not approved; this page is educational only.
Albiglutide
Incretin mimetic (GLP-1 receptor agonist)
Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.
Efpeglenatide
Incretin mimetic (GLP-1 receptor agonist)
Efpeglenatide is a long-acting GLP-1 receptor agonist built from an exendin-based peptide conjugated to an antibody Fc fragment for extended duration. It has been evaluated in large clinical programs, including the AMPLITUDE-O cardiovascular-outcomes trial, and remains investigational — it is not authorized by Health Canada.

References & further reading

  1. 1.Wikipedia — Lixisenatide
  2. 2.PubChem — compound summary for Lixisenatide (CID 90472060)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Lixisenatide educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.